Psychiatric disorders
Psychiatric illnesses including schizophrenia, major depressive disorder (MDD), bipolar disorder (BD), post-traumatic stress disorder (PTSD), panic disorder, and alcohol use disorders are common and leading causes of global disability. Conventionally, diagnosis and treatment of these disorders has relied solely on clinicical observation of symptoms and inference of underlying neural dysfunction. Recently, however, technological advances have allowed for direct measurement of brain functioning in these disorders, and there has been increased interest in the exploration of sensory processing deficits involved. In this context, MMN is regarded as a ‘breakthrough biomarker’ for advancing the understanding and treatment of psychiatric illness. As MMN is among the most widely studied translational biomarkers and has already undergone extensive psychometric validation (e.g. reliability, suitability for use as a repeated measure, sensitivity to pharmacologica and non-pharmacological interventions), it is widely used for development of new treatments for brain disorders.